Teva Octreotide Acetate Injectable Suspension Recall Expanded in 2026 for Sterility Concerns
Teva Pharmaceuticals recalled 1,897 cartons of Octreotide Acetate for Injectable Suspension distributed nationwide in the USA after an FDA inspection flagged sterility concerns. The recall is due to lack of assurance of sterility from the contract manufacturer. Consumers and healthcare providers should stop using the product immediately and contact Teva for guidance.
Product Details
Model numbers/lot numbers: Lot 4401619; Exp. 09/30/2026; 4501005; Exp. 03/31/2027
Where sold: Nationwide in the USA
When sold: Unknown
Price: Unknown
The Hazard
Lack of Assurance of Sterility due to quality system deficiencies identified during an FDA inspection of the contract manufacturer.
Reported Incidents
No injuries or incidents have been reported.
What to Do
1 Stop using the product immediately.
2 Contact Teva Pharmaceuticals USA, Inc. or your healthcare provider for guidance.
3 Recall notices may include replacement or refund guidance; refund information is not provided in the recall materials.
Contact Information
FDA recall page: https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0404-2026
Provider/Teva consumer affairs: Not specified in recall materials.